Dennis Podlesak - 15 Sep 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
15 Sep 2022
Net transactions value
-$1,399,680
Form type
4
Filing time
16 Sep 2022, 17:34:10 UTC
Previous filing
03 Feb 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $422,429 +66,840 +88% $6.32 142,603 15 Sep 2022 Direct
transaction SNDX Common Stock Sale $1,617,381 -66,840 -47% $24.20 75,763 15 Sep 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $34,248 +5,419 +7.2% $6.32 81,182 16 Sep 2022 Direct
transaction SNDX Common Stock Sale $126,982 -5,419 -6.7% $23.43 75,763 16 Sep 2022 Direct F1, F3
transaction SNDX Common Stock Options Exercise $41,631 +6,556 +8.7% $6.35 82,319 16 Sep 2022 Direct
transaction SNDX Common Stock Sale $153,625 -6,556 -8% $23.43 75,763 16 Sep 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -66,840 -100% $0.000000* 0 15 Sep 2022 Common Stock 66,840 $6.32 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -6,556 -100% $0.000000* 0 16 Sep 2022 Common Stock 6,556 $6.35 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -5,419 -100% $0.000000* 0 16 Sep 2022 Common Stock 5,419 $6.32 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 192,600 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.
F2 The sale prices ranged from $23.37 to $24.64
F3 The sale prices ranged from $22.96 to $24.07
F4 This option is fully vested.